Hunter Melissa G, Jacob Anand, O'donnell Lynn C, Agler Amanda, Druhan Lawrence J, Coggeshall K Mark, Avalos Belinda R
Bone Marrow Transplantation Program, The Arthur G. James Cancer Hospital, Ohio State University, Columbus 43210, USA.
J Immunol. 2004 Oct 15;173(8):5036-45. doi: 10.4049/jimmunol.173.8.5036.
Mutations in the G-CSF receptor (G-CSFR) in patients with severe congenital neutropenia (SCN) are postulated to contribute to transformation to acute myelogenous leukemia (AML). These mutations result in defective receptor internalization and sustained cellular activation, suggesting a loss of negative signaling by the G-CSFR. In this paper we investigated the roles of SHIP and cytokine-inducible Src homology 2 protein (CIS) in down-modulating G-CSFR signals and demonstrate that loss of their recruitment as a consequence of receptor mutations leads to aberrant signaling. We show that SHIP binds to phosphopeptides corresponding to Tyr744 and Tyr764 in the G-CSFR and that Tyr764 is required for in vivo phosphorylation of SHIP and the formation of SHIP/Shc complexes. Cells expressing a G-CSFR form lacking Tyr764 exhibited hypersensitivity to G-CSF and enhanced proliferation, but to a lesser degree than observed with the most common mutant G-CSFR form in patients with SCN/AML, prompting us to investigate whether suppressor of cytokine signaling proteins also down-modulate G-CSFR signals. G-CSF was found to induce the expression of CIS and of CIS bound to phosphopeptides corresponding to Tyr729 and Tyr744 of the G-CSFR. The expression of CIS was prolonged in cells with the SCN/AML mutant G-CSFR lacking Tyr729 and Tyr744, which also correlated with increased G-CSFR expression. These findings suggest that SHIP and CIS interact with distal phosphotyrosine residues in the G-CSFR to negatively regulate G-CSFR signaling by limiting proliferation and modulating surface expression of the G-CSFR, respectively. Novel therapeutic approaches targeting inhibitory pathways that limit G-CSFR signaling may have promise in the treatment of patients with SCN/AML.
重度先天性中性粒细胞减少症(SCN)患者的粒细胞集落刺激因子受体(G-CSFR)突变被认为会促使其转化为急性髓系白血病(AML)。这些突变导致受体内化缺陷和细胞持续激活,提示G-CSFR负信号传导功能丧失。在本文中,我们研究了SHIP和细胞因子诱导的Src同源2蛋白(CIS)在下调G-CSFR信号中的作用,并证明由于受体突变导致它们募集缺失会导致信号异常。我们发现SHIP与G-CSFR中对应于Tyr744和Tyr764的磷酸肽结合,并且Tyr764是SHIP体内磷酸化及SHIP/Shc复合物形成所必需的。表达缺乏Tyr764的G-CSFR形式的细胞对G-CSF表现出超敏反应且增殖增强,但程度低于SCN/AML患者中最常见的突变G-CSFR形式,这促使我们研究细胞因子信号传导抑制蛋白是否也下调G-CSFR信号。发现G-CSF可诱导CIS表达以及与G-CSFR中对应于Tyr729和Tyr744的磷酸肽结合的CIS表达。在缺乏Tyr729和Tyr744的SCN/AML突变G-CSFR的细胞中,CIS表达延长,这也与G-CSFR表达增加相关。这些发现表明,SHIP和CIS分别通过限制增殖和调节G-CSFR的表面表达,与G-CSFR中的远端磷酸酪氨酸残基相互作用,从而负向调节G-CSFR信号传导。针对限制G-CSFR信号传导的抑制途径的新型治疗方法可能对SCN/AML患者的治疗具有前景。